Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Angers – page 7

681 clinical trials in Angers, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Angers at a glance
681
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

681 trials in Angers

Open in trial search

Prostate cancer

Recruiting

A study of saruparib with radiotherapy and hormone therapy for men with high-risk prostate cancer who have a BRCA gene mutation

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:AstraZeneca AB

Pleural mesothelioma

Recruiting

Study of fianlimab plus cemiplimab with chemotherapy or cemiplimab with chemotherapy for patients with pleural mesothelioma who have not received prior treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Renal cell carcinoma

Recruiting

A Study of Belzutifan and Zanzalintinib Compared to Cabozantinib in Patients with Advanced Kidney Cancer that Returned After Previous Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Triple negative breast cancer

Recruiting

Testing sacituzumab govitecan and trastuzumab deruxtecan in alternating pattern for patients with HER2-low triple-negative breast cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sacituzumab Govitecan
  • Sponsor:Unicancer

Thrombocytopenia

Recruiting

Study of romiplostim given before heart surgery in patients with low platelet counts to improve blood clotting after surgery

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Romiplostim
  • Sponsor:Centre Hospitalier Universitaire De Nantes

Endometrial cancer+1

Recruiting

A study comparing BNT323 with chemotherapy in patients with HER2-expressing recurrent endometrial cancer who received previous treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:DB-1303
  • Sponsor:BioNTech SE

Hepatitis alcoholic

Recruiting

Study of N-acetylcysteine and prednisolone combination versus extended prednisolone treatment in patients with severe alcoholic hepatitis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Acetylcysteine
  • Sponsor:Centre Hospitalier Universitaire De Lille

Bronchiolitis+1

Recruiting

Study of nirsevimab and RSV vaccine (Abrysvo) for prevention of respiratory syncytial virus infection in infants during their first year of life

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Nirsevimab
  • Sponsor:Centre Hospitalier Annecy Genevois

PIK3CA related overgrowth spectrum

Recruiting

Study of alpelisib in children and adults with PIK3CA-Related Overgrowth Spectrum (PROS)

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Novartis Pharma AG

Breast cancer metastatic

Recruiting

Study of Trastuzumab Deruxtecan Blood Levels in Normal Weight and Overweight Patients with Metastatic Breast Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Oncopole Claudius Regaud

Colorectal cancer metastatic

Recruiting

Study of FOLFOX or FOLFIRI chemotherapy with fruquintinib or bevacizumab as second-line treatment for patients with metastatic colorectal cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Fondation Franc.Cancerologie Digestive

Non-small cell lung cancer+1

Recruiting

Study of trastuzumab deruxtecan with pembrolizumab versus platinum chemotherapy with pembrolizumab for patients with untreated HER2-positive non-small cell lung cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Angers

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on multiple myeloma, breast cancer, and various forms of lung cancer. Studies are evaluating new combination therapies and treatment approaches for both early-stage and advanced cancers.

  • Triple-negative breast cancer treatments
  • Advanced non-small cell lung cancer therapies
  • Head and neck squamous cell carcinoma studies

Research includes investigation of novel drug combinations and immunotherapy approaches.

02 Cardiovascular Studies

Clinical research addressing heart failure prevention and acute myocardial infarction management. Studies are exploring innovative pain management approaches and preventive treatments.

  • Heart failure risk reduction
  • Pulmonary hypertension treatments
  • Emergency cardiac care interventions

Focus on both acute care solutions and long-term prevention strategies.

03 Immunology and Transplantation

Comprehensive research in kidney transplantation and immune disorders, including studies on preventing rejection and managing immunosuppression.

  • Transplant rejection prevention
  • Immune response monitoring
  • Novel immunotherapy approaches

Trials aim to improve long-term outcomes for transplant recipients and immune disorder patients.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.